Bangalore News Network
Advertise With BNN
About Us
Bangalore News Network
Industry & Commerce
Social Service
Fashion & Entertainment
Other News
Trending News
List All News
Request News Coverage

Roche launches Vabysmo® (Faricimab), the first and only bispecific antibody for the eye, to treat two leading causes of Vision loss

Vabysmo targets and inhibits two disease pathways that cause neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) ** Vabysmo’s revolutionary dual-pathway mechanism of action (MoA) neutralises angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) to restore vascular stability for patients living with nAMD and DME ** Vabysmo is the only injectable eye medicine approved simultaneously for nAMD and DME, with flexible/ less frequent dosing regimens based on patient need
Bengaluru | Written by: BNN Team | Updated: 05-03-2024 | Views: 598
Industry & Commerce - L&T Technology Services celebrates innovatio ...
Launches - Acer Launches Acerpure Consumer Electronic ...
Launches - Compass Group India launches its larges ...

(L to R) :  Chief Corporate Affairs, Communication and CSR Officer, Roche; Dr. Chaitra Jaidev, Head of Vitreoretina Services - Narayana Nethralaya Eye Institute (Bangalore); Mr Rahul Kamath- Chief Operating Officer, Karnataka Cluster, Roche

Roche Pharma India marked its foray into the Ophthalmology space by launching Vabysmo® (faricimab) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DME are two leading causes of vision loss worldwide.

Vabysmo® is the first and only dual-pathway-inhibitor that uniquely targets and inhibits two disease pathways linked to a number of vision threatening retinal conditions. It neutralises both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) which are key proteins involved in the development and progression of retinal conditions, contributing to vision loss by destabilising blood vessels in the eye.

As the world’s first bispecific antibody, Vabysmo is a single molecule designed to target and inhibit the effects of two targets, providing the benefits of two medicines in one. Current treatment options target VEGF alone, and therefore only partially address the biology of the disease. By blocking both pathways involving Ang-2 and VEGF-A, Vabysmo® offers people the first new MoA (mechanism of action) in more than 15 years for nAMD and close to a decade for DME, stabilising blood vessels in the retina and improving vision outcomes.

Vabysmo® has the potential to transform the existing Standard of Care (SoC) as the burden associated with currently available treatment options for nAMD and DME such as frequent eye injections (typically required every one to two months) and physician visits can lead to under treatment and less-than-optimal vision outcomes. Vabysmo® offers better treatment durability and flexible dosing, with patients requiring eye injections at intervals of up to once in four months, while achieving similar vision gains and anatomical improvements.

Commenting on the launch, V Simpson Emmanuel, CEO and Managing Director, Roche Pharma India, said, "We believe more should be done to meet the needs of people living with retinal conditions and to preserve sight. While there is strong awareness and action for cataract and other frontal eye-disorders, retinal conditions are often diagnosed late or neglected, leading to vision loss. The launch of Vabysmo® marks our entry into the ophthalmology space in India, underscoring our commitment to bring the best-in-class innovations to the country. With fewer eye injections over time, while also improving and maintaining vision and anatomy, Vabysmo® offers a more convenient and effective treatment schedule for patients, their caregivers and healthcare systems.”

“nAMD and DME can limit a person’s ability to read, drive and recognise faces. Even simple everyday activities may become challenging as the disease progresses. Vabysmo® offers the ‘Latest’ (world’s first dual pathway inhibition), ‘Fastest’ (fastest drying & effective disease control) and ‘Longest’ (extended durability up to 4 months) treatment option to patients,” said Dr. Viraj Suvarna, Chief Medical Officer at Roche Pharma India.

Dr. Chaitra Jaidev, Head of Vitreoretina Services - Narayana Nethralaya Eye Institute, said: “DME and nAMD are sight-threatening conditions that necessitate frequent hospital visits and injections, significantly impacting patients' lives. Additionally patients greatly fear getting injected in the eye. A treatment that targets both anti-VEGF and anti-ANG-2 pathways could be transformative. Its dual mode of action offers advantages like faster drying of edema and potentially longer durability compared to current therapies. This approach has the potential to significantly improve outcomes, reduce treatment frequency, and enhance a patient's quality of life. As retina specialists, we see this as a game changer in our field, offering new hope and possibilities for our patients battling these complex retinal diseases.”
Preventable and treatable vision loss is a growing global public health concern. A staggering 2.2 billion people1 live with vision impairment worldwide that could either be prevented or treated. Retinal conditions are now affecting more people than ever before. More than ~300 million patients globally2 and ~11 million patients in India3 suffer from retinal vision loss. India is home to one-third of the blind population of the world. Furthermore, in India, the prevalence of wAMD and severe DME stands at approximately 4 million4.

Vabysmo® (faricimab) was first approved by the USFDA in January 2022. It is today available in across 90+ countries and more than 2 million doses have been administered till date.

About Us
Advertise With Us
Feedback / Contact Us
Industry & Commerce
Fashion & Entertainment
Copyright Policy
Terms of Use
Privacy Policy
Bangalore News Network
Send Your Feedback Here
Copyright © 2003 Bangalore News Network.
Software by Probiz IT & ITES